Is RPRX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

544 people get RPRX articles and Market Currents by email alert.

Get email alerts on RPRX »

HEADLINES:

Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results

GlobeNewswire (May 10, 2013)
Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead of Schedule

GlobeNewswire (May 2, 2013)
Repros' Proellex(R) in Breast Cancer Phase 2 Study in Collaboration With Northwestern University

GlobeNewswire (Apr 29, 2013)
Repros to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

GlobeNewswire (Apr 29, 2013)
Shorts Are Covering These 4 Highly Shorted, Cash-Rich Small Caps
Kapitall • Tue, Apr 23 • 1 Comment
Repros Reports Issuance of Two Additional U.S. Androxal(R) Patents

GlobeNewswire (Apr 10, 2013)
5 Stocks To Watch Next Week For Gains
Brian Nichols • Sun, Apr 7 • 8 Comments
Can Repros Therapeutics Maintain Its Momentum?
Efsinvestment • Thu, Apr 4 • 4 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Mon, Apr 1 • 1 Comment
Repros Moves Up On Phase III Data, Both Co-Endpoints Met
Brian L. Wilson • Sun, Mar 31 • 11 Comments
5 Stocks To Watch For Gains This Week
Brian Nichols • Sat, Mar 30 • 11 Comments
Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal(R)

GlobeNewswire (Mar 27, 2013)
American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study for Podium Presentation at Annual Meeting

GlobeNewswire (Mar 25, 2013)
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2012 Financial Results

GlobeNewswire (Mar 18, 2013)
Repros Therapeutics ZA-301 Study: Odds Of Success Have Just Increased
Biotech Sage • Wed, Mar 13 • 18 Comments
FDA Grants Repros an End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 3 Study Design

GlobeNewswire (Feb 28, 2013)
Repros Reports FDA Recommends Pivotal Study ZA-301 of Androxal(R) to be Completed as Originally Planned

GlobeNewswire (Feb 21, 2013)
3 Micro-Caps With Sustainable Cash Flows
Matt Schilling • Wed, Feb 13 • 8 Comments
Repros Therapeutics Corporate Update

GlobeNewswire (Feb 11, 2013)
Insider Buying Trends: Are These Cash Rich Companies Ready To Rally?
Kapitall • Tue, Feb 5

To learn more about Seeking Alpha Pro, click here.

Can Repros Therapeutics Maintain Its Momentum?
Efsinvestment • Thu, Apr 4 • 4 Comments
Repros Moves Up On Phase III Data, Both Co-Endpoints Met
Brian L. Wilson • Sun, Mar 31 • 11 Comments
Repros Therapeutics ZA-301 Study: Odds Of Success Have Just Increased
Biotech Sage • Wed, Mar 13 • 18 Comments
A Pullback Would Be Healthy For Repros Therapeutics
Adam Gefvert • Thu, Sep 20, 2012 • 4 Comments
A Closer Look At Repros Therapeutics
Brian L. Wilson • Sun, Jul 29, 2012 • 5 Comments
Repros Therapeutics: More Holes Than A Block Of Swiss Cheese
Timeless Wealth • Tue, Jun 5, 2012 • 7 Comments
One Biotech That Defies Sensible Fundamentals
Ross Klosterman • Thu, May 31, 2012 • 4 Comments
Top Insider Trades May 14, 2012: Repros
InsiderInsights • Tue, May 15, 2012 • 6 Comments
Back On Track: Repros Therapeutics Products Continues Advancement
Cockrell Group • Thu, Apr 12, 2012 • 1 Comment
2 Potential Game Changers for Repros Therapeutics
Investment U • Sun, May 15, 2011
A Three-Way Strategy on Repros Therapeutics
optionMONSTER • Mon, Oct 26, 2009 • 1 Comment
Repros Therapeutics: Circling the Drain to Zero
Biomaven • Wed, Sep 2, 2009 • 11 Comments
Why Michelle Obama Is Likely to Support Repros Therapeutics
Elliot Eisenberg • Mon, Jul 13, 2009 • 6 Comments
Red Flags at Repros Therapeutics
Ian Bezek • Sun, Jan 25, 2009 • 5 Comments
Five Reason Repros Therapeutics Is Hitting 52-Week Highs
Elliot Eisenberg • Fri, Jan 9, 2009 • 3 Comments
What's With Efficacy Capital/Repros Therapeutics' Standstill Agreement?
Elliot Eisenberg • Tue, Jan 22, 2008

Shorts Are Covering These 4 Highly Shorted, Cash-Rich Small Caps
Kapitall • Tue, Apr 23 • 1 Comment
5 Stocks To Watch Next Week For Gains
Brian Nichols • Sun, Apr 7 • 8 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Mon, Apr 1 • 1 Comment
5 Stocks To Watch For Gains This Week
Brian Nichols • Sat, Mar 30 • 11 Comments
3 Micro-Caps With Sustainable Cash Flows
Matt Schilling • Wed, Feb 13 • 8 Comments
Insider Buying Trends: Are These Cash Rich Companies Ready To Rally?
Kapitall • Tue, Feb 5
Insiders Love These 3 Highly Shorted Healthcare Stocks
Kapitall • Wed, Jan 23 • 1 Comment
Insider Buying Trends: Are These Cash Rich Companies Ready To Rally?
Kapitall • Fri, Jan 4
Insiders Love These 5 Highly Shorted Biotech Stocks
Kapitall • Wed, Aug 8, 2012 • 4 Comments
Insiders Love These 10 Outperforming Healthcare Stocks
Kapitall • Tue, Jul 10, 2012
Russell 3000 U.S. Healthcare Additions For June 2012
EXPstocktrader • Mon, Jun 11, 2012 • 2 Comments
3 Biotech Stocks Outperforming On Insider, Hedge Fund Buying
Kapitall • Sun, Jun 3, 2012 • 3 Comments
5 Insider Stock Picks On Winning Streaks
Kapitall • Sun, Jun 3, 2012
Biotech Hedge Fund Bought This Surging Stock, And Other 13D/G Filings Last Week
GuruFundPicks • Sun, May 27, 2012 • 1 Comment
10 Stocks Favored By Hedge Funds And Company Insiders
Kapitall • Fri, May 25, 2012
4 Highly Liquid Biotech Stocks Being Snapped Up By Insiders
Kapitall • Fri, May 25, 2012
The Strongest Small Caps In The Market
Benzinga • Tue, May 22, 2012 • 10 Comments
7 Outperforming Healthcare Stocks With Strong Insider Buying
Kapitall • Wed, May 16, 2012 • 1 Comment
Public Offerings Create Investing Opportunities In Biotech Sector
The Swiss Trader • Tue, May 15, 2012 • 3 Comments
2 Plunging And 1 Surging Healthcare Stocks Insiders Bought Last Week, Other Noteworthy Trades
GuruFundPicks • Sun, May 13, 2012 • 1 Comment

There are no Transcripts on RPRX.

Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results

GlobeNewswire (May 10, 2013)
Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead of Schedule

GlobeNewswire (May 2, 2013)
Repros' Proellex(R) in Breast Cancer Phase 2 Study in Collaboration With Northwestern University

GlobeNewswire (Apr 29, 2013)
Repros to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

GlobeNewswire (Apr 29, 2013)
Repros Reports Issuance of Two Additional U.S. Androxal(R) Patents

GlobeNewswire (Apr 10, 2013)
Movers & Shakers: Thursday movers: Apple falls 17% in first quarter

at MarketWatch.com (Mar 28, 2013)
Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal(R)

GlobeNewswire (Mar 27, 2013)
American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study for Podium Presentation at Annual Meeting

GlobeNewswire (Mar 25, 2013)
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2012 Financial Results

GlobeNewswire (Mar 18, 2013)
FDA Grants Repros an End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 3 Study Design

GlobeNewswire (Feb 28, 2013)
Repros Reports FDA Recommends Pivotal Study ZA-301 of Androxal(R) to be Completed as Originally Planned

GlobeNewswire (Feb 21, 2013)
Repros Therapeutics Corporate Update

GlobeNewswire (Feb 11, 2013)
Repros Updates Guidance for Top Line Results From First Pivotal Androxal(R) Study to Q3 2013

GlobeNewswire (Jan 28, 2013)
Repros Reports Core 1-Year DEXA Study Fully Enrolled Ahead of Schedule and Provides Update for Androxal(R) Clinical Program

GlobeNewswire (Jan 7, 2013)
Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective and Well Tolerated in Phase 2 for Uterine Fibroids

GlobeNewswire (Jan 3, 2013)
Repros Presents Androxal(R) and Proellex(R) Clinical Updates at The Lazard Capital Markets 9th Annual Healthcare Conference

GlobeNewswire (Nov 13, 2012)
Repros Therapeutics Inc.(R) Reports Third Quarter 2012 Financial Results

GlobeNewswire (Nov 13, 2012)
Repros to Present Androxal(R) and Proellex(R) Clinical Updates at the Lazard Capital Markets 9th Annual Healthcare Conference

GlobeNewswire (Nov 5, 2012)
FDA Reclassifies Proellex(R) Clinical Hold Status: Repros to Proceed With Phase 2 Study of Low Dose Oral Proellex(R) in the Treatment of Endometriosis

GlobeNewswire (Oct 8, 2012)
Repros Provides Clinical Update for Androxal(R) Phase 3 Program

GlobeNewswire (Sep 12, 2012)

RPRX vs. ETF Alternatives

Company Description

Currently, there's no company description for RPRX.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 9:31 AM Repros Therapeutics (RPRX): Q1 EPS of -$0.41 misses by $0.06. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, March 28, 9:14 AM Repros Therapeutics (RPRX) soars before the bell after the company says main goals met in testosterone drug study. It's a good day to be a stockholder - shares +73%, recovering big losses incurred in January. 5 Comments [Healthcare]
Thursday, March 28, 9:10 AM Premarket gainers: RPRX +75%. CTIC +14%. ONCY +8%. EXM +7%. DECK +6%. XONE +6%.
Losers: TWO -8%. FIVE -7%. GME -5%. 1 Comment [On the Move]
Monday, March 25, 2:47 PM Repros Therapeutics (RPRX +6.9%) ticks higher today after the American Urological Association accepted key data on it's Androxal for presentation at the annual meeting in San Diego in May. The data that will be presented are from studies of two doses of Androxal with open label on demand Testim gel in 120 patients with secondary hypogonadism, and aims to prove that Androxal may provide effective therapy in men with the condition, particularly in those wishing to preserve fertility. Comment! [Healthcare, On the Move]
Monday, March 18, 1:30 PM Repros Therapeutics (RPRX -2.9%) trades down after its Q4 per share loss comes in wider than expected, primarily due to increased expenses in clinical development related to Androxal and Proellex and higher operational expenses. R&D expenses also increased 54% to approximately $13.3M, as compared to $8.7M for the same period in the prior year. Comment! [Healthcare, Earnings, On the Move]
Monday, March 18, 9:31 AM Repros Therapeutics (RPRX): Q4 EPS of -$0.47. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, February 28, 9:46 AM Repros Therapeutics (RPRX -0.9%) says it will meet with the FDA in the second half of May to discuss Phase 3 trials for the company's Proellex treatment for uterine fibroids. Last week, Repros' shares surged on news that its Androxal Phase 3 program has been given a receipt of written guidance by the agency. (PR) Comment! [Healthcare]
Thursday, February 21, 1:15 PM Midday top 10 gainers: CBMX +115%. WH +85%. PRKR +48%. RPRX +31%. CLRX +26%. MKTG +23%. ALIM +20%. JAXB +17%. BRY +17%. CBR +15%.
Midday top 10 losers: PAY -39%. GENT -23%. EBIX -23%. PATK -16%. XRSC -16%. CMGE -16%. CHLN -16%. RBCN -15%. RFMD -15%. ANTP -14%. Comment! [On the Move]
Thursday, February 21, 9:23 AM Repros Therapeutics (RPRX) +33.1% premarket on news its Androxal Phase 3 program has been given a receipt of written guidance from the FDA, effectively a notice that the FDA has accepted its study plans. Androxal is a treatment to normalize testosterone and luteinizing hormone levels in men. 1 Comment [Healthcare, On the Move]
Thursday, February 21, 9:10 AM Premarket gainers: PRKR +38%. RPRX +31%. NVGN +28%. BRY +22%. PEGA +17%. LOCK +7%. LNCO +5%. ALXA +5%.
Losers: GENT -37%. PAY -34%. GFI -17%. ALU -7%. WLT -6%. TSLA -5%. Comment! [On the Move]
Monday, February 11, 1:51 PM Repros Therapeutics (RPRX +2.5%) moves up after saying that it's conducting a 6-month 500 subject open label study as part of an FDA requirement for Androxal, and it's sent a "request for guidance" letter to the agency regarding two other pivotal studies on the drug as well. Additionally, the company also says its requested an end of Phase 2 meeting before the end of April for its vaginal Proellex program for the treatment of uterine fibroids. 1 Comment [Healthcare, On the Move]
Tuesday, January 29, 9:10 AM Premarket gainers: KERX +18%. PLXT +10%. VLO +8%. OPK +7%. HES +7%. RPRX +6%. AKS +6%.
Losers: OXF -24%. ANAC -23%. VMW -19%. LXK -6%. RBS -6%. STX -6%. EDU -5%. Comment! [On the Move]
Monday, January 28, 12:45 PM Midday top 10 gainers: KERX +79%. FURX +51%. SHIP +39%. CTC +18%. HGSH +17%. SINO +14%. RSH +12%. CPBC +11%. OCZ +11%. ACAD +10%.
Midday top 10 Losers: NVGN -61%. RPRX -27%. JOSB -18%. TRMD -16%. BYFC -15%. JVA -12%. DDD -11%. PRCP -10%. SSYS -9%. AKS -8%. Comment! [On the Move]
Monday, January 28, 9:28 AM Repros Therapeutics (RPRX) -6.7% premarket as it plans to release data from a clinical trial of its Androxal treatment for secondary hypogonadism during Q3 instead of Q2 amid marked discrepancies in baseline sperm counts in the study. RPRX says it doesn’t expect the developments to affect the timing of its new drug application to the FDA. Comment! [Healthcare, On the Move]
Monday, January 7, 2:45 PM Repros Therapeutics (RPRX +1.7%) provides a clinical update of its Phase 3 DEXA study, saying that recruiting is running better than expected, and that 83% of men with secondary hypogonadism are on target to be successfully treated with no testosterone levels achieved beyond the normal range. Enrollment should ensure mid-2014 NDA submission. Comment! [Healthcare, On the Move]
Thursday, January 3, 4:16 PM Repros Therapeutics (RPRX -3.2%) finishes lower after reporting top line results from its Phase 2 study of vaginally administered Proellex in the treatment of symptomatic fibroids. The results from the study suggest the 12 mg dose may provide clinical benefit to women suffering from symptomatic uterine fibroids. The company plans to request an end of Phase 2 meeting with the FDA as soon as practicable. Comment! [Healthcare]

Kapitall
Shorts Are Covering 4 Highly Shorted, Cash-Rich Small Caps $PANL $RPRX $VECO $VHC http://seekingalpha.com/a/t69r
Apr 23, 12:25 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

SEC Trader
Stacking G's over here!! $KO Yesterday, $RPRX Is going off the hook today!!! Bought long into $RPRX 3 months ago @$8!! Year high $19.19 now!
Apr 18, 12:24 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
New Upgrades (3/28/13): $ABCO, $ALDW, $APA, $CERN, $ESV, $EVEP, $FL, $FLR, $GBX, $GOLD, $HOT, $KOF, $LH, $MDVN, $MON, $NOV, $RKT, $RPRX
Apr 1, 9:05 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it.
Mar 29, 5:26 AM
Reply (3)

• !Report Abuse
View all 3 replies
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
Mar 29, 5:18 PM
• !Report Abuse
yourmama6799: Rashar for President!!!
Mar 29, 6:43 PM
• !Report Abuse
Add a reply...

140 characters

SEC Trader
NICE $RPRX !¡!¡ Up 74% on news of clinical trial updates!!!! Keep it moving +++>
Mar 28, 12:21 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Morning Coffee, Day Trading Watchlist: $XONE $FIVE $RPRX | http://bit.ly/Zr8Tyr
Mar 28, 9:20 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

SEC Trader
Nothing on $RPRX stock in over 8 months with all of its up's & downs??
Mar 22, 2:40 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
RPRX - 100% Barchart technical buy signal - 5 new highs and up 27.51% in the last month - Relative Strength Index 72.31%
8/22/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dr. Kris
$RPRX breaking out of rising wedge pattern on 6x volume. Possible front-running of upcoming FDA mtg on Proellex Phase 2 protocol?
8/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Cockrell Group
Ascendiant Capital Markets initiated coverage of Repros Therapeutics $RPRX with a "STRONG BUY" rating and a price target of $6.
4/11/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it.
Mar 29, 5:26 AM
Reply (3)

• !Report Abuse
View all 3 replies
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
Mar 29, 5:18 PM
• !Report Abuse
yourmama6799: Rashar for President!!!
Mar 29, 6:43 PM
• !Report Abuse
Add a reply...

140 characters

RPRX Repros Therapeutics Inc.

RPRX

Repros Therapeutics Inc.